Proprotein convertase type 9 (PCSK9)

Proprotein convertase type 9 (PCSK9)

C026/0273 Rights Managed

Request low-res file

530 pixels on longest edge, unwatermarked

Request/Download high-res file

Uncompressed file size: 53.6MB

Downloadable file size: 1.5MB

Price image Pricing

Please login to use the price calculator


Credit: ALFRED PASIEKA/SCIENCE PHOTO LIBRARY

Caption: Molecular rendering of the enzyme proprotein convertase subtilisin/kexin type 9 (PCSK9) (top) and an antibody (bottom). When PCSK9 binds to an LDLR, the receptor is destroyed along with the LDL particle. But if PCSK9 does not bind, the receptor can return to the surface of the cell and remove more cholesterol. New biopharmaceutical monoclonal antibody drugs act as a treatment to lower LDL cholesterol for adults who have a severe form of hereditary high cholesterol (familial hypercholesterolemia (FH) and people who require additional lowering of LDL cholesterol, when diet and statin treatment have not worked. PCSK9 inhibitors reduce the amount of cholesterol in the blood by improving the liver's ability to recycle low-density lipoprotein receptors. The PCSK9 inhibitor Alirocumab, known as brand name Praluent (Sanofi/Regeneron) is the first monoclonal antibody drug approved by the FDA

Release details: Model release not required. Property release not required.

Keywords: alirocumab, antibody, approved, biopharmaceutical, cholesterol, convertase subtilisin/kexin type 9, drug, drugs, enzyme, familial hypercholesterolemia, fda, fh, hereditary high cholesterol, inhibitors, ldl, lipoprotein, liver, low-density, molecular, molecule, monoclonal, pcsk9, praluent, proprotein, receptors, regeneron, sanofi, statin, treatment

Licence fees: A licence fee will be charged for any media (low or high resolution) used in your project.